NCT04438382 2026-04-02
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis
Eastern Cooperative Oncology Group
Phase 2 Terminated
Clinical Trials
58 trialsNCT04179864 2026-03-10
CELLO-1
Ipsen
Phase 1/2 Terminated
NCT01995058 2026-01-08
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Exelixis
Phase 2 Terminated
NCT05032183 2025-08-11
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02420717 2025-06-08
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04752163 2025-05-23
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04556617 2025-04-08
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Opna Bio LLC
Phase 1/2 Terminated
NCT04517435 2025-02-07
ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma
Case Comprehensive Cancer Center
Phase 1/2 Terminated
NCT02626455 2024-12-11
CHRONOS-4
Bayer
Phase 3 Terminated
NCT04745832 2024-11-04
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
MEI Pharma, Inc.
Phase 3 Terminated
NCT03777982 2024-09-19
Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
Dana-Farber Cancer Institute
Phase 3 Terminated
NCT03488225 2024-07-16
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04907227 2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT04933617 2024-07-09
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01186328 2024-02-01
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Terminated
NCT03649841 2023-10-26
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
University of Washington
Phase 2 Terminated
NCT00736450 2023-10-24
Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
University of Nebraska
Phase EARLY_PHASE1 Terminated
NCT00003910 2023-07-05
Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT00060346 2023-06-29
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT01390584 2023-06-29
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT01746173 2023-01-30
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT02531308 2022-09-28
DLBCL
Rush University Medical Center
Phase 2 Terminated
NCT03150056 2022-08-10
Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer
GlaxoSmithKline
Phase 1 Terminated
NCT01681433 2022-07-11
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02685267 2021-04-09
Doce/Enza
Prostate Cancer Clinical Trials Consortium
Phase 2 Terminated
NCT02844582 2021-01-25
Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
University of California, Davis
Phase 2 Terminated
NCT03827473 2020-06-25
ACADEMIC
University of Utah
Phase 2 Terminated
NCT03093272 2020-04-09
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT02758132 2019-11-08
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
University of Hawaii
Phase 2 Terminated
NCT02379390 2019-06-21
PRIMCAB
Sanofi
Phase 2 Terminated
NCT01287741 2019-04-12
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Hoffmann-La Roche
Phase 3 Terminated
NCT00996502 2019-03-27
Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer
Columbia University
Phase 1/2 Terminated
NCT01994590 2019-03-19
Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02855359 2019-03-11
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT00074490 2018-12-31
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00809341 2018-09-25
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00527124 2018-08-09
Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01925612 2018-06-21
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Seagen Inc.
Phase 2 Terminated
NCT02419469 2018-06-11
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01522443 2018-05-23
COMET-2
Exelixis
Phase 3 Terminated
NCT01717898 2018-03-27
A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
University of California, San Francisco
Phase 1/2 Terminated
NCT00562965 2018-01-09
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
Pfizer
Phase 3 Terminated
NCT00882206 2017-12-28
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00772668 2017-12-11
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL
University of Miami
Phase NA Terminated
NCT00348816 2017-12-08
Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Terminated
NCT01145508 2017-09-19
Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00450385 2017-06-23
R-CHOP
University of Miami
Phase 2 Terminated
NCT00995722 2017-06-02
EPITOME'
University of Miami
Phase 3 Terminated
NCT00088881 2017-05-25
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00879619 2017-02-01
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
University of California, Irvine
Phase 1/2 Terminated